Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease - Concepedia

Concepedia

Publication | Open Access

Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

DOI Full Paper Access

13

Citations

14

References

2025

Year

W Bakker, Hiddo J.L. Heerspink, Stefan P. Berger, Christoph Wanner, Sunil V. Badve, Clare Arnott, Alferso C Abrahams, Joost C. van den Born, Tim C van Faassen, M. Gelens,

Nephrology Dialysis Transplantation

Abstract

The Renal Lifecycle trial aims to investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure, mortality and safety in three subgroups of patients with advanced CKD.

References

	Year	Citations

Page 1